Screener
AbCellera Biologics Inc. ABCL Receipt of grant funding
Receipt of grant funding at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept abcl:ProceedsFromReceiptOfGrantFunding.
The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001703057-26-000046
| Line item | Six months ended June 30, 2025 | Six months ended June 30, 2026 |
|---|---|---|
| Purchases of property and equipment | (24,001) | (5,963) |
| Purchase of marketable securities | (291,542) | (308,184) |
| Proceeds from marketable securities | 303,437 | 293,557 |
| Receipt of grant funding | 6,448 | 6,955 |
| Long-term investments and other assets | (18,218) | (105) |
| Net cash used in investing activities | (23,876) | (13,740) |
| Cash flows from financing activities: | ||
| Proceeds from deferred government contributions and other | 2,595 | 13,585 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is AbCellera Biologics Inc.'s receipt of grant funding?
- AbCellera Biologics Inc. (ABCL) reported receipt of grant funding of $5.59M in Q2 2026.
- How has AbCellera Biologics Inc.'s receipt of grant funding changed year-over-year?
- AbCellera Biologics Inc.'s receipt of grant funding increased by 3.0% year-over-year, from $5.43M to $5.59M.
- What is the long-term trend for AbCellera Biologics Inc.'s receipt of grant funding?
- Over 3 years (2022 to 2025), AbCellera Biologics Inc.'s receipt of grant funding has grown at a 9.1% compound annual growth rate (CAGR), from $16.43M to $21.34M.
- What does receipt of grant funding mean?
- Receipt of grant funding as reported by AbCellera Biologics Inc. Common Shares.
Ask your AI about AbCellera Biologics Inc.'s receipt of grant funding.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude